Meeting
2024 ASCO Genitourinary Cancers Symposium
A study to evaluate patient benefit/risk preferences for treatment of metastatic prostate cancer (mPC) in Hong Kong: A discrete choice experiment.
Authors
Chi-Fai Ng
SH Ho Urology Centre, Hong Kong, Hong Kong
Chi-Fai Ng , Yeuk-Lam Hong , Kenneth C.W. Wong , Wing-Yan Kong , Chi-ho Leung , Pui-Tak Lai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 104)
DOI
10.1200/JCO.2024.42.4_suppl.104
Abstract #
104
Poster Bd #
D19
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Optimal sequential therapy for metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors in the up-front era.
First Author: Yushi Naito
Poster
2022 ASCO Annual Meeting
Phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer.
First Author: Neal D. Shore
Poster
2022 ASCO Genitourinary Cancers Symposium
KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab + lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
First Author: Gero Kramer
Poster
2022 ASCO Genitourinary Cancers Symposium
Effect of neoadjuvant chemotherapy (NAC) on patient preferences for adjuvant treatment in muscle-invasive urothelial carcinoma (MIUC): A multi-country discrete choice experiment (DCE).
First Author: Edward I Broughton